PL376703A1 - Pochodne proliny wykazujące powinowactwo do podjednostki Ó-2-Ű kanału wapniowego - Google Patents

Pochodne proliny wykazujące powinowactwo do podjednostki Ó-2-Ű kanału wapniowego

Info

Publication number
PL376703A1
PL376703A1 PL376703A PL37670303A PL376703A1 PL 376703 A1 PL376703 A1 PL 376703A1 PL 376703 A PL376703 A PL 376703A PL 37670303 A PL37670303 A PL 37670303A PL 376703 A1 PL376703 A1 PL 376703A1
Authority
PL
Poland
Prior art keywords
affinity
calcium channel
channel alpha
proline derivatives
delta subunit
Prior art date
Application number
PL376703A
Other languages
English (en)
Inventor
David James Rawson
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of PL376703A1 publication Critical patent/PL376703A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL376703A 2002-10-31 2003-10-22 Pochodne proliny wykazujące powinowactwo do podjednostki Ó-2-Ű kanału wapniowego PL376703A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0225379.7A GB0225379D0 (en) 2002-10-31 2002-10-31 Therapeutic proline derivatives

Publications (1)

Publication Number Publication Date
PL376703A1 true PL376703A1 (pl) 2006-01-09

Family

ID=9946940

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376703A PL376703A1 (pl) 2002-10-31 2003-10-22 Pochodne proliny wykazujące powinowactwo do podjednostki Ó-2-Ű kanału wapniowego

Country Status (39)

Country Link
EP (1) EP1558246B1 (pl)
JP (2) JP3940416B2 (pl)
KR (2) KR100750782B1 (pl)
CN (1) CN100418525C (pl)
AP (1) AP2005003295A0 (pl)
AR (1) AR041865A1 (pl)
AT (1) ATE468116T1 (pl)
AU (1) AU2003269411B2 (pl)
BR (1) BR0315839A (pl)
CA (1) CA2499698C (pl)
CO (1) CO5550430A2 (pl)
CR (1) CR7802A (pl)
DE (1) DE60332646D1 (pl)
DK (1) DK1558246T3 (pl)
EA (1) EA009767B1 (pl)
EC (1) ECSP055769A (pl)
ES (1) ES2343624T3 (pl)
GB (1) GB0225379D0 (pl)
GE (1) GEP20074127B (pl)
GT (1) GT200300234A (pl)
HK (1) HK1081441A1 (pl)
HR (1) HRP20050351A2 (pl)
IL (4) IL167799A (pl)
IS (1) IS7754A (pl)
MA (1) MA27481A1 (pl)
MX (1) MXPA05004662A (pl)
NL (1) NL1024677C2 (pl)
NO (1) NO330496B1 (pl)
OA (1) OA12954A (pl)
PA (1) PA8587201A1 (pl)
PE (1) PE20040553A1 (pl)
PL (1) PL376703A1 (pl)
RS (1) RS20050333A (pl)
TN (1) TNSN05122A1 (pl)
TW (2) TW200633699A (pl)
UA (1) UA81437C2 (pl)
UY (1) UY28043A1 (pl)
WO (1) WO2004039367A1 (pl)
ZA (1) ZA200502305B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005097741A1 (en) * 2004-04-05 2005-10-20 Pfizer Limited Process for the recrystallisation of proline derivates
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
JP5138589B2 (ja) * 2006-06-06 2013-02-06 浜松ホトニクス株式会社 神経因性疼痛を抑制するピロリジン類縁体及びその製造方法
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX2015017864A (es) 2013-06-26 2016-04-15 Zhejiang Jiuzhou Pharm Co Ltd Metodo de preparacion de derivados de acido pirrolidina-2-carboxil ico.
WO2015003723A1 (en) * 2013-07-12 2015-01-15 Københavns Universitet Substituted 4-proline derivatives as iglur antagonists
CN104418785A (zh) * 2013-09-05 2015-03-18 浙江九洲药业股份有限公司 一种药物中间体的制备方法
CN104829513B (zh) * 2014-02-11 2019-02-19 浙江九洲药业股份有限公司 一种2-羧基-4-甲氧基甲基吡咯烷衍生物的制备方法
CN104844495A (zh) * 2015-06-05 2015-08-19 武汉理工大学 一种(2s,4s)-4-苯硫基-l-脯氨酸盐酸盐的合成方法
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions
TW202026281A (zh) * 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
EP3904339A1 (en) * 2020-04-28 2021-11-03 Esteve Pharmaceuticals, S.A. Alkylaminoproline derivatives as alfa-2-delta-1 blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
CA1144930A (en) * 1978-08-11 1983-04-19 Miguel A. Ondetti Mercaptoacyl derivatives of substituted prolines
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
ZA817601B (en) * 1980-11-24 1982-10-27 Squibb & Sons Inc Carboxyalkyl amino acid derivatives of various substituted prolines
JPH07504155A (ja) * 1991-04-19 1995-05-11 シオス・ノヴァ・インコーポレイテット ブラジキニンアンタゴニストペプチド
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6156726A (en) * 1996-08-02 2000-12-05 Elan Pharmaceuticals, Inc. Voltage-gated calcium channel antagonist and method
JP3196106B2 (ja) * 1997-03-27 2001-08-06 参天製薬株式会社 ロイコトリエンａ４ヒドロラーゼ阻害剤
JP2002516312A (ja) * 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives

Also Published As

Publication number Publication date
GB0225379D0 (en) 2002-12-11
ATE468116T1 (de) 2010-06-15
RS20050333A (en) 2007-06-04
NL1024677C2 (nl) 2005-07-04
UY28043A1 (es) 2004-05-31
TW200416030A (en) 2004-09-01
CN100418525C (zh) 2008-09-17
AR041865A1 (es) 2005-06-01
EA009767B1 (ru) 2008-04-28
IL201966A (en) 2011-06-30
KR20070046213A (ko) 2007-05-02
WO2004039367A1 (en) 2004-05-13
OA12954A (en) 2006-10-13
TNSN05122A1 (fr) 2007-05-14
JP2006516115A (ja) 2006-06-22
MXPA05004662A (es) 2005-06-08
CA2499698A1 (en) 2004-05-13
AU2003269411A1 (en) 2004-05-25
EP1558246B1 (en) 2010-05-19
KR20050065646A (ko) 2005-06-29
ES2343624T3 (es) 2010-08-05
BR0315839A (pt) 2005-09-27
HK1081441A1 (en) 2006-05-19
HRP20050351A2 (en) 2005-10-31
NL1024677A1 (nl) 2004-05-06
JP2006328078A (ja) 2006-12-07
ZA200502305B (en) 2006-11-29
IL201967A (en) 2011-06-30
EA200500581A1 (ru) 2005-12-29
CR7802A (es) 2007-10-23
NO20051407D0 (no) 2005-03-17
UA81437C2 (en) 2008-01-10
CA2499698C (en) 2009-01-20
JP3940416B2 (ja) 2007-07-04
EP1558246A1 (en) 2005-08-03
IS7754A (is) 2005-03-17
TW200633699A (en) 2006-10-01
IL167799A (en) 2011-03-31
GT200300234A (es) 2004-06-23
KR100750782B1 (ko) 2007-08-20
IL201965A (en) 2011-03-31
DK1558246T3 (da) 2010-08-09
GEP20074127B (en) 2007-06-11
AU2003269411B2 (en) 2009-06-18
PA8587201A1 (es) 2004-05-26
PE20040553A1 (es) 2004-08-28
DE60332646D1 (de) 2010-07-01
CN1711081A (zh) 2005-12-21
JP4555263B2 (ja) 2010-09-29
AP2005003295A0 (en) 2005-06-30
MA27481A1 (fr) 2005-08-01
NO20051407L (no) 2005-07-26
CO5550430A2 (es) 2005-08-31
NO330496B1 (no) 2011-05-02
ECSP055769A (es) 2005-08-11

Similar Documents

Publication Publication Date Title
HK1081441A1 (en) Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
GB2408318B (en) Spotlight
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
GB0318894D0 (en) Composition
GB0203421D0 (en) Composition
GB0227244D0 (en) Composition
GB0208608D0 (en) Composition
GB0203280D0 (en) Anti-glycolytic composition
GB0211924D0 (en) Composition
GB0318152D0 (en) Composition
GB0218241D0 (en) Composition
AU2003299204A8 (en) Focal calcium channel modulation
HK1082517A1 (en) Oil-barrier composition
EP1495751A4 (en) hair dye
GB0229286D0 (en) Composition
GB0213767D0 (en) Composition
EP1636339A4 (en) NEW CALCIUM CHANNEL
GB0203616D0 (en) Composition
AU2003301258A8 (en) Calcium channel agonists for psychotherapeutic use
PL363419A1 (pl) Ortopedyczny korektor krzywizn
GB0200437D0 (en) Composition
GB0326793D0 (en) Composition
GB0225246D0 (en) Composition
GB0226447D0 (en) Composition

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)